Global Melanoma Drugs and Companies Pipeline Review H2 2017 adds Exclusive Research on “Frontier Pharma: Melanoma Therapeutics – Cytokine and Multiple Targeted Small Molecules and mAbs Dominate Pipeline and First-in-Class Innovation” reports to its database.


Melanoma is a type of cancer that begins in the melanocytes, often in moles or other pigmented tissues. It most commonly affects the skin, as cutaneous melanoma; however it can also affect other pigmented tissues, such as the eye or intestines, as extracutaneous melanoma. It is the deadliest form of skin cancer and remains one of the most aggressive and treatment-resistant human cancers.


GET SAMPLE REPORT @            


Global prevalence of the disease has risen significantly in the past several decades, primarily due to an increase in exposure to UV light and/or sunlight. This has resulted in an increase in developmental interest with regard to improving disease management, particularly in the advanced metastatic setting.

The emergence over the past decade of novel targeted therapies and therapies that manipulate the immune response has improved treatment options for patients. These new drug classes have been highly commercially successful with blockbuster products that are now well established within the treatment algorithm.

In spite of these developments, there are still significant unmet needs for both cutaneous and extracutaneous melanoma, and the rationale for investment in first-in-class innovation remains strong. First-in-class products account for a considerable proportion of the melanoma pipeline, which is substantially larger than the current market.



Rising global prevalence and unmet need have resulted in an increase in developmental interest

– What is the pathophysiology of melanoma?

– How has the emergence of new drug classes in the past decade impacted the treatment algorithm?

– What are the most significant unmet needs within the market?

The melanoma pipeline is large and innovative in comparison with the current market

– Which molecule types and molecular targets are most prominent within the pipeline?

– Which first-in-class targets are most promising?

– How does the ratio of first-in-class targets to first-in-class products differ by stage of development and molecular target class?

– Do melanoma products attract high deal values?

– Which molecule types and molecular targets dominate the deals landscape?

– Which first-in-class pipeline products have no prior involvement in licensing or co-development deals?


Reasons to buy

– Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment strategies currently available.

– Visualize the composition of the melanoma market in terms of the dominant classes of therapies. Unmet needs are highlighted to allow a competitive understanding of current gaps in the market.

– Analyze the melanoma pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target. There are signs in the pipeline that the industry is seeking novel approaches to meet unmet needs within melanoma.

– Assess the therapeutic potential of first-in-class targets. Using a proprietary matrix, first-in-class products have been assessed and ranked according to clinical potential. Promising novel targets have been further reviewed in greater detail.

– Identify commercial opportunities in the melanoma deals landscape by analyzing trends in licensing and co-development deals and assessing melanoma therapies that are not yet involved in deals, and may be potential investment opportunities.


Table of Content: Key Points

1 Table of Contents 2

    1.1 List of Tables 4

    1.2 List of Figures 4

2 Executive Summary 6

    2.1 Unmet Need Remains Despite Significant Advances in Therapy Options 6

    2.2 Moderately Sized but Innovative Pipeline 6

    2.3 Deals Landscape Offers Significant Investment Opportunities for First-in-Class Products 6

3 The Case for Innovation in the Melanoma Market 7

    3.1 Growing Number of Opportunities for Biologic Products 8

    3.2 Diversification of Molecular Targets 8

    3.3 Innovative First-in-Class Product Developments Remain Attractive 8

    3.4 Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product Innovation 9

    3.5 Sustained Innovation 9

    3.6 GBI Research Report Guidance 10

4 Clinical and Commercial Landscape 11

    4.1 Disease Overview 11

    4.2 Types of Melanoma 11

    4.3 Disease Symptoms 13

      4.3.1 Cutaneous Melanoma 13

      4.3.2 Ocular Melanoma 13

      4.3.3 Mucosal Melanoma 13

      4.3.4 Melanoma of the Internal Organs and Soft Tissue 13

      4.3.5 Advanced Melanoma 13

    4.4 Diagnosis 14

      4.4.1 Cutaneous Melanoma 14

      4.4.2 Ocular Melanoma 14





Contact Info:                                                         

NORAH TRENT                                                      

Partner Relations & Marketing Manager

Ph: +1-646-845-9349 (US)                

Ph: +44 208 133 9349 (UK)                                                   


Get in touch:




Media Contact
Company Name:
Contact Person: Norah Trent
Phone: +1 646 845 9349, +44 208 133 9349
City: New York City
State: NY
Country: United States